Comparing the current results to its competitors, Compass Pathways Plc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 222.43 %, recorded in the same quarter.
Compass Pathways Plc's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical, biopharmaceutical, specialty pharmaceutical, and biotechnology firms, as well as academic institutions, governmental agencies, and medical research organizations. In the U.S., two pharmacotherapies are currently approved for treatment-resistant depression (TRD): Spravato (esketamine), marketed by Janssen, and generic olanzapine and fluoxetine hydrochloride capsules. Competitors may possess greater financial resources, technical expertise, human capital, clinical trial experience, regulatory approvals, brand recognition, and collaborative partnerships. Smaller and early-stage companies can also be significant competitors, particularly through collaborations with larger firms. Additionally, there is a growing number of companies focused on discovering new psychedelic compounds.
October 29, 2025
Navigating New Frontiers: Dr. Jeffrey Jonas Joins Compass Pathways in a Strategic Board Appointment Amidst Financial Trials In an era where mental health is increasingly taking the centre stage in global discourse, biotechnology firms are rapidly evolving to meet the complex demands of the sector. A company at the vanguard of this evolution is Compass Pathways Plc (Nasdaq: CMPS), a pioneering entity committed to transforming the treatment landscape through scientific innovation. In a recent strategic move, Compass Pathways announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, a decision that promises to inject seasoned expertise into the company s leadership.Dr. Jonas, a distinguished fig...
January 10, 2025
Compass Pathways plc, a biotechnology company traded on Nasdaq under the symbol CMPS, has been forefront in the burgeoning field of mental health innovation. The company s recent pricing of an underwritten offering of over 24 million American Depositary Shares (ADSs), in addition to pre-funded warrants, underscores its critical strategy in financing its pivotal projects. These pre-funded warrants represent a potential purchase of over 11 million ADSs, essentially offering institutional investors an enticing and flexible entry into the company s vision. However, the company s financial results highlight a stark contrast to its competitors, necessitating a closer examination of Compass Pathways’ positioning ...
December 18, 2024
LONDON - In a significant development for the biotechnology sector, Compass Pathways plc (Nasdaq: CMPS) has announced that it will be added to the NASDAQ Biotechnology Index (NBI). The addition will go into effect prior to the market opening on December 23, 2024. This recognition underlines Compass Pathways commitment to enhancing patient access to innovative mental health solutions backed by scientific evidence. The NASDAQ Biotechnology Index is a crucial benchmark that tracks the performance of publicly traded biotechnology companies that are listed on the NASDAQ stock market. This index comprises companies that engage in biopharmaceutical development and seek to address unmet medical needs. The inclusio...
May 8, 2024
In a recent open-label phase 2 study, Compass Pathways plc announced positive top-line results regarding the safety and efficacy of investigational COMP360 psilocybin treatment in patients suffering from post-traumatic stress disorder (PTSD). This article aims to outline the key findings of the study, highlighting the significant and durable improvement in symptoms observed over a 12-week period and the favorable safety profile of COMP360.Study Design and Patient Demographics:The study enrolled 22 patients diagnosed with PTSD and assessed the safety and tolerability of COMP360 psilocybin treatment. The primary was to evaluate the safety endpoint, while secondary efficacy outcomes included measures of diseas...
May 2, 2024
London, May 02, 2024 - Compass Pathways plc (Nasdaq: CMPS), a renowned biotechnology company committed to advancing patient access to evidence-based mental health solutions, has joined forces with Mindful Health Solutions (MHS), a leading provider of innovative behavioral health care in the United States. This significant research collaboration aims to develop a scalable and cost-effective delivery model for COMP360 psilocybin treatment, pending approval for treatment-resistant depression (TRD). Driven by a shared vision to revolutionize mental health care, Compass and MHS are exploring various approaches to ensure COMP360 reaches patients in diverse care settings.The collaboration between Compass Pathways a...
Alzamend Neuro Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapeutics for Alzheimer's disease and other neurological disorders. Their business model revolves around conducting extensive research and clinical trials to develop groundbreaking treatments that address the underlying causes of these debilitating conditions. With a focus on creating value for patients, healthcare providers, and shareholders, they aim to bring effective therapies to market and improve the quality of life for those affected by neurodegenerative diseases.
Clearmind Medicine Inc operates as a healthcare company that provides innovative mental health solutions, leveraging advanced technology and research-backed treatments. Their business model focuses on developing and delivering personalized mental health therapies, utilizing a combination of telehealth services, virtual reality technology, and data-driven treatment plans.
Bright Minds Biosciences Inc is a biotechnology company that focuses on developing novel therapies for neuropsychiatric diseases. Their business model involves conducting research and development to discover and develop proprietary drug candidates, with the aim of partnering or licensing them to pharmaceutical companies for further clinical development and commercialization.
Sources:
Compass Pathways Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Compass Pathways Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
